EU Mercosur FTA puts at risk access to medicines in Brazil

From the 29th of November to the 8th of December, a new round of negotiations is taking place in Brussels regarding the FTA agreement between the EU and Mercosur. One of the most sensitive issue regarding the IP chapter is the one related to patents and public health. In this framework, an impact assesment of the IP section proposed by the EU on a country llike Brazil was conducted. The result is that the agreement as currently designed would have a negative impact on public access to medicines in Brazil by highly increasing public expenditures in this matter. Mandatory exhaustion of IPR, extended protection period and data exclusivity are one of the most harmful clauses for Brazil, hence the rejection from Mercosur regarding the TRIPS plus measure put forward by the EU.

Source: Intellectual Property Watch